絞り込み

16546

広告

1033件中 141件~160件表示    検索結果をPubMedで見る PubMedで見る

Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment.

Brief report: Afatinib and cetuximab in four patients with EGFR exon 20 insertion positive advanced non-small-cell lung cancer.

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.

Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.

Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells.

Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Lung adenocarcinoma presenting as intramedullary spinal cord metastasis: Case report and review of literature.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.

Simultaneous targeting of EGFR, HER2 and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.

Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.

Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.

[Metastatic Brain Tumor from Lung Adenocarcinoma Presenting a Unique Radiographic Pattern during Afatinib Treatment:A Case Report].

Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187.

Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation.

Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.

  1. 4
  2. 5
  3. 6
  4. 7
  5. 8
  6. 9
  7. 10
  8. 11
  9. 12
  10. 13
Sort by
※並べ替えは表示に時間がかかります